US Patent 7915443 Sulfoximines as kinase inhibitors
Patent 7915443 was granted and assigned to Allergan, Inc. on March, 2011 by the United States Patent and Trademark Office.
All edits
Edits on 27 Nov, 2023
Golden AI
Edits made to:
Article (+198 characters)
Article
Patent abstract
The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
Edits on 19 Sep, 2023
Golden AI
Edits made to:
Infobox (+6 properties)
Infobox
Patent Inventor Names
Clarence Eugene Hull, III0
Julie A. Wurster0
Richard C. Yee0
Shimiao Wang0
Sougato Boral0
Thomas C. Malone0
Edits on 20 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 18 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07915443 Sulfoximines as kinase inhibitors US Patent 7915443 Sulfoximines as kinase inhibitors
Infobox
Patent Number
079154430
Patent Number
79154430
Edits on 27 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
079154430
Date of Patent
March 29, 2011
0Patent Application Number
119417530
Date Filed
November 16, 2007
0Official Website
Patent Primary Examiner
Edits on 19 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 7 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07915443 Sulfoximines as kinase inhibitors
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07915443
Date of patent
March 29, 2011
Patent application number
11941753
Date Filed
November 16, 2007
Patent primary examiner
Find more entities like US Patent 7915443 Sulfoximines as kinase inhibitors
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.